Clinical trial
A Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intra Articular (IA) Injection of UMC119-06-05 in Adult Subjects With Mild to Moderate Knee Osteoarthritis(KOA).
NCT04893174 is registered in ClinicalTrials.gov with Meridigen Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intra Articular (IA) Injection of UMC119-06-05 in Adult Subjects With Mild to Moderate Knee Osteoarthritis(KOA).
- Lead sponsor
- Meridigen Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 15, 2022
- Completion date
- June 30, 2025
- Enrollment
- 6 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.